Comprehensive medical diagnostics and related solutions firm, Todos Medical Ltd (OTCMKTS:TOMDF) on May 2, 2022, announced that the majority-owned subsidiary 3CL Pharma, Ltd. has received a fresh certificate of free sale from the US Food & Drug Administration. The label gives both a 5-day support dosing regimen as well as 30-day maintenance dosing regimen of Tollovid Maximum Strength.
Market Reaction
On Monday, TOMDF stock moved up 2.17% to $0.0117 with more than 5.01 million shares, compared to its average volume of 6.10 million shares. The stock moved within a range of $0.0113 – 0.0130 after opening trade at $0.0113.
Todos Medical Receives New FDA Certificate of Free Sale for Tollovid® Max Strength Including 5 Day Dosing, 30 Day Dosing and 3CL Protease (3CLpro, Mpro, Nsp5) Inhibitor Claim
It also reconfirms the 3CL protease in vitro inhibitor language permitted on prior labels for Tollovid. The firm is of the view that the new CFS will facilitate customers in easily navigatingthe product.
The firm will be working on adding a supplement to future sales along with pamphlet giving extra information. The firm will also carry-on selling bottles from inventory manufactured in first half of previous year
Tollovid, also known as Tollovid Maximum Strength, has significantly reduced 3CL protease inhibition strength per pill. It is a dietary supplement which has showed vitro activity for inhibiting the 3CL protease. Tollovid is not approved for diagnosing, treating, preventing, or curing any disease. This includes COVID or Long COVID.Tollovid can be bought on Amazon or even through the company’s store, on its website.
Both Tollovid and Tollovid Daily are dietary supplement products made from natural ingredients helping in maintaining healthy immune function.
Traders Review
TOMDF stock is trading below the 20-Day and 50-Day Moving averages of $0.0151 and $0.0222 respectively. Moreover, the stock is trading below the 200-Day moving average of $0.0386.
